These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10752591)

  • 1. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
    Frucht S; Fahn S; Chin S; Dhawan V; Eidelberg D
    Mov Disord; 2000 Mar; 15(2):340-3. PubMed ID: 10752591
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Understanding and treating levodopa-induced dyskinesias].
    Hadj Tahar A; Bédard PJ
    Tunis Med; 1998 Dec; 76(12):437-47. PubMed ID: 10093483
    [No Abstract]   [Full Text] [Related]  

  • 4. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
    Manson AJ; Iakovidou E; Lees AJ
    Mov Disord; 2000 Mar; 15(2):336-7. PubMed ID: 10752589
    [No Abstract]   [Full Text] [Related]  

  • 5. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinsonian rigidity, dopa-induced dyskinesia and chorea--dynamic studies on the basal ganglia-thalamocortical motor circuit using PET scan and depth microrecording.
    Hirato M; Ishihara J; Horikoshi S; Shibazaki T; Ohye C
    Acta Neurochir Suppl; 1995; 64():5-8. PubMed ID: 8748574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
    Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia?
    Aron AR; Obeso J
    Mov Disord; 2012 Mar; 27(3):339-40. PubMed ID: 22411844
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Snow BJ; Macdonald L; Mcauley D; Wallis W
    Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 12. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
    Espay AJ; Lang AE
    JAMA Neurol; 2017 Jun; 74(6):633-634. PubMed ID: 28459962
    [No Abstract]   [Full Text] [Related]  

  • 13. Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
    Pouclet H; Derkinderen P; Lebouvier T
    Clin Neurol Neurosurg; 2013 Feb; 115(2):235-6. PubMed ID: 22743235
    [No Abstract]   [Full Text] [Related]  

  • 14. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
    Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
    Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 17. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri KR; Jenner P; Antonini A
    Mov Disord; 2019 Jun; 34(6):816-819. PubMed ID: 30983023
    [No Abstract]   [Full Text] [Related]  

  • 18. [Physiopathology of the dyskinesias induced by L-dopa].
    Grandas F; López-Ariztegui N
    Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
    McFarthing K; Prakash N; Simuni T
    J Parkinsons Dis; 2019; 9(3):449-465. PubMed ID: 31356217
    [No Abstract]   [Full Text] [Related]  

  • 20. Measuring motor complications in clinical trials for early Parkinson's disease.
    Marras C; Lang AE
    J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):143-6. PubMed ID: 12531932
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.